News

With this round, the biotechnology firm has raised more than $300m so far. The funding round was led by Ally Bridge Group, TCG Crossover, and Temasek. Among the

Biotechnology firm Regenxbio and AbbVie have closed the previously announced license and collaboration deal for the development and commercialisation of the former’s gene therapy, RGX-314. The new gene

Merck has received antitrust clearance from the competition authorities in Germany and Austria to tender offer for the acquisition of clinical-stage biopharmaceutical firm Acceleron Pharma. The latest move

The UK’s National Institute for Health and Care Excellence (NICE) has recommended AstraZeneca’s dapagliflozin as a treatment for people with chronic kidney disease (CKD). It has been recommended

EffRx Pharmaceuticals has received marketing authorisation from Swissmedic for Bronchitol to treat cystic fibrosis (CF) in adults and in children aged six years and above. Developed by Australian

Novavax has completed the rolling submission to the World Health Organization (WHO) for emergency use listing (EUL) of its Covid-19 vaccine candidate, NVX-CoV2373. The company has submitted all

SNX281 is Stingthera’s small molecule agonist of the Stimulator of Interferon Genes (STING) protein. An anti-programmed death receptor-1 (anti-PD-1) therapy, Keytruda is a registered trademark of Merck &

Dunad Therapeutics and Novartis have signed a strategic collaboration and license agreement to develop next generation targeted protein degrader therapies. Under the deal, Novartis gets the sole rights

Synthekine and Merck have signed a global research collaboration and license agreement to develop novel cytokine-based therapeutics. As part of the collaboration, the companies will discover, develop, and